Compare Amylx Pharmaceuticals Inc (AMLX) vs KLA Corp. (KLAC) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

KLA Corporation (KLAC) trades at $231.52, up 0.88% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.94 exceeding the $0.917 estimate. Revenue grew to $12.16 billion in 2025, driving a net income margin of 35.66%. A 1:10 stock split is scheduled for June 12, 2026, and a $2.30 dividend was paid in June 2026.

KLAC's outlook is supported by AI-driven semiconductor equipment demand and consistent earnings outperformance, but high valuation ratios (P/E 65.57, P/S 23.38) pose risks if growth slows. Analysts maintain a buy consensus with a $239.86 price target, though competitive pressures and market volatility remain concerns for shareholders.